Six Unproven Peptides Hit Pharmacy Shelves as FDA Looks Away

On Oct. 29, 2026, an HHS policy driven by Health and Human Services Secretary Robert F. Kennedy Jr. will let specialized pharmacies make and sell six unapproved wellness peptides — and no regulator will verify what's in them.

The six compounds are BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. None has been proved safe and effective. None is approved by the U.S. Food and Drug Administration. Until now, consumers could only get them through the gray market — online sellers and wellness stores exploiting legal loopholes.

Kennedy has pushed this outcome for months. Earlier in 2026, he pressured the FDA to reconsider peptides the agency had restricted in 2023. He also appointed eight new members to the FDA advisory committee that handles the question — every one of them tied to businesses selling or promoting peptides, according to reporting cited by health law professor Ana Santos Rutschman of Villanova University. In July 2026, the committee voted 8-6 to expand access.

That vote came over the objections of the agency's own scientists, who told the committee repeatedly there was not enough information about the safety and efficacy of the peptides to justify letting compounding pharmacies sell them.

What are these peptides?

Peptides are short chains of amino acids — the building blocks of proteins. More than 7,000 occur naturally in the human body. Some peptides have become legitimate, FDA-approved medicines: insulin, and GLP-1 weight-loss drugs like Ozempic and Wegovy.

The difference is process. Pharmaceutical peptides go through clinical trials and FDA approval. Wellness peptides sold by influencers and online vendors get no regulatory evaluation at all.

Two of the six newly permitted compounds carry particular social-media cachet. Influencers call the BPC-157-plus-TB-500 combination the "Wolverine stack," after the Marvel superhero, and recommend it for building muscle mass and speeding postworkout recovery. Kennedy himself promoted these peptides in podcasts and on his Take Back Your Health tour.

How does the new policy work?

The policy allows small compounding pharmacies — businesses licensed to produce a narrow set of drugs not FDA-approved — to sell the six peptides by prescription.

The legal instrument is "enforcement discretion." The FDA retains authority to regulate the products but tells pharmacies there will be no legal consequences for selling them. Critics describe it as the agency looking the other way.

Regulators sometimes use this tool for low-risk situations. During a recent shortage of weight-loss drugs, the FDA let compounders step in to ease supply gaps.

The track record gets darker when risk is real. Diagnostic tests for Lyme disease and breast and ovarian cancer sat on the market under enforcement discretion for years. Genomic Health began selling a breast cancer screening test in 2008; scientists questioned its accuracy in 2011, and in 2014 it was confirmed the test had delivered false negatives to cancer patients. Theranos's blood tests also fell outside active FDA oversight — a gap that, as Rutschman notes, helped Elizabeth Holmes conceal her fraud for years.

Who checks the product?

Kennedy and other proponents argue pharmacies are a safer channel than online sellers. The new policy's wording echoes that claim, implying pharmacist oversight makes the substances safer.

The law says otherwise. Compounding pharmacies have no obligation to test ingredients from outside suppliers. Federal law requires the FDA to evaluate drugs before sale and monitor production — but those requirements do not apply to compounded drugs. The FDA's own website warns that the lack of regulation opens the door to "poor compounding practices" and that some compounded products can be unsafe or ineffective.

In short: more places will sell these peptides, and no regulator will check their safety or efficacy.

What's the business signal?

FDA law normally incentivizes companies to research their products. By choosing not to regulate, Rutschman argues, the agency signals it isn't interested in having these substances studied — a decision that may discourage exactly the research that could uncover legitimate medical applications for them.

By Grace Kim